KalVista Pharmaceuticals Inc. has released a corporate presentation detailing significant developments and future plans for its novel therapy for Hereditary Angioedema $(HAE)$, Sebetralstat. The presentation highlights Sebetralstat's potential to become the first oral on-demand therapy for HAE, with a strong safety profile and efficacy comparable to injections. Key milestones include the completion of pediatric trial enrollment in March 2025, a U.S. launch in June 2025 following FDA review, and subsequent launches in Germany, the UK, Japan, and other regions through 2026. The global on-demand HAE treatment market is valued at $3 billion. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.